Overview

Lorlatinib Combinations in Lung Cancer

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. - This research study involves four study drugs. - Lorlatinib - Binimetinib - Crizotinib - TNO155

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborators:

Array BioPharma
Pfizer

Treatments:

Crizotinib